Effect of Intradermal Dosage Injection (PCDX). Diseases of the digestive system
Conditions
Interventions
Intervention 1: Intervention group: Intervention group: First, in all subjects with maximum sterile precautions, it is taken in the intravenous route and then given to a patient randomly. Monitoring o
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Symptoms of diagnostic and endoscopic interventions of upper or lower GI procedures, or both Male and female at least 18 years old Otherwise, the patient is healthy or ill with mild systemic disease, which is well controlled Urinalysis or pregnancy serum in female patients at the start of the study Being able to provide informed consent is signed
Exclusion criteria
Exclusion criteria: Patients under the age of 18 years or those unable to sign an informed consent Surgical procedures or those who have had an open surgical procedure for endoscopic surgery within one week Chronic opioid use or benzodiazepine for anxiety, insomnia and chronic pain Severe hyperactivity (heart rate <45 bpm) Low blood pressure (systolic blood pressure less than 90 mmHg) Advanced heartbeats, AV blocks, second and third grade, and a branch block of the sinusoidal bacillary block that is detected during the monitoring stages in the EKG, which lasts for more than 15 seconds The chronic use of beta blockers, the calcium channel block, which may cause chronic diarrhea and life threatening bradycardia Detection of ECG 12 Lead by QT. The patient will typically not be screened for this variable Patients with upper and lower GI bleeding and patients with unstable hemodynamics Pregnant pregnant women Patients with advanced liver failure Patients who have been treated with any drug in the last 30 days Undesirable reactions to medications or predscheks in previous use History of mental disorder or use of psychiatric drugs Patients with pain in the intestinal tract Gastrectomy history There may be serious illnesses simultaneously
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Low blood pressure. Timepoint: mmediately after the intervention, after 5 minute, after 10 minute, after 20 minute, after 40 minute, after 60 minute, after 1.5 hour, after 2 hour, after 3 hour, . Method of measurement: Monitoring, Sphygmomanometer tool.;Nausea. Timepoint: Immediately after the intervention, after 5 minute, after 10 minute, after 20 minute, after 40 minute, after 60 minute, after 1.5 hour, after 2 hour, after 3 hour, . Method of measurement: Ask the patient. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Hojjat Pourfathi
Tabriz University of Medical Sciences
Outcome results
None listed